- Home
- HTH vs SUPN Comparison
HTH vs SUPN Comparison
Compare HTH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | SUPN |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | 778 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HTH | SUPN |
|---|---|---|
| Price | $37.74 | $42.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $41.67 | ★ $61.75 |
| AVG Volume (30 Days) | 240.0K | ★ 507.8K |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | $152,188,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $1.89 | $23.21 |
| Revenue Next Year | $2.53 | $54.85 |
| P/E Ratio | $29.63 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $30.78 | $40.51 |
| 52 Week High | $40.41 | $59.68 |
Technical Indicators
Market Signals| Indicator | HTH | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 47.74 |
| Support Level | $36.73 | $42.54 |
| Resistance Level | $37.30 | $52.33 |
| Average True Range (ATR) | 0.59 | 1.34 |
| MACD | -0.14 | 0.26 |
| Stochastic Oscillator | 2.66 | 61.76 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.